María Hernández‐Sánchez

Author

Also Known As

Carlos Méndez-Vázquez, Hernandez-Sanchez, M., Hernández-Sánchez, M., Hernández-Sánchez, María, M Hernández, M. Calles Hernández, M. Hernandez-Sanchez, M. Hernández-Sánchez, M. Hernández‐Sánchez, María Hernández-Sánchez

119

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Universidad de Salamanca Instituto de Investigación Biomédica de Salamanca Centro de Investigación del Cáncer Hospital Universitario Infanta Leonor Complejo Hospitalario de Salamanca

About

María Hernández‐Sánchez is an author at Universidad de Salamanca specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	486
2	Cell Biology	4	4	423
3	Health Sciences	1	1	26
4	Public Health	1	1	12
5	Epidemiology	1	1	12

María Hernández‐Sánchez

Publications

1.1K

Citations

H-Index

Page 1

	Year	Citations
Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies Romain Guièze, Vivian M. Liu, Daniel Rosebrock, Cancer Cell Lymphoid NeoplasiaMitochondrial FunctionMedicineMalignant Blood DisorderImmunology	2019	348
Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY Larry Mansouri, Birna Þorvaldsdóttir, Lesley‐Ann Sutton, Leukemia	2022	50
Molecular Characterization of Chronic Lymphocytic Leukemia Patients with a High Number of Losses in 13q14 Ana E. Rodriguez, José‐Ángel Hernández‐Rivas, Rocío Benito, PLoS ONE	2012	48
Mutations in TP53 and JAK2 are independent prognostic biomarkers in B-cell precursor acute lymphoblastic leukaemia Maribel Forero‐Castro, Cristina Robledo, Rocío Benito, British Journal of Cancer	2017	48
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of <i>TP53/ATM FISH</i> deletions Anna Puiggros, Rosa Collado, Marı́a José Calasanz, Oncotarget	2017	47
Next-generation sequencing and FISH studies reveal the appearance of gene mutations and chromosomal abnormalities in hematopoietic progenitors in chronic lymphocytic leukemia Miguel Quijada‐Álamo, María Hernández‐Sánchez, Cristina Robledo, Journal of Hematology & Oncology	2017	47
The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of <i>BCR/ABL in vitro</i> and in a xenograft model of chronic myeloid leukemia Ignacio García‐Tuñón, María Hernández‐Sánchez, José Luis Ordóñez, Oncotarget ApoptosisImmunologyCell DeathCrispr/cas9 SystemCancer Biology	2017	39
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition Miguel Quijada‐Álamo, María Hernández‐Sánchez, Verónica Alonso-Pérez, Leukemia	2020	35
Chronic lymphocytic leukemia patients with<scp><i>IGH</i></scp>translocations are characterized by a distinct genetic landscape with prognostic implications Claudia Pérez‐Carretero, María Hernández‐Sánchez, Teresa González, International Journal of Cancer	2020	34
Association between <i><scp>CFH</scp>,<scp> CFB</scp>,<scp> ARMS</scp>2, <scp>SERPINF</scp>1, <scp>VEGFR</scp>1</i> and <i><scp>VEGF</scp></i> polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age‐related macular degeneration Estefanía Cobos, Sergio Recalde, Jaouad Anter, Acta Ophthalmologica	2017	33

Page 1